These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 15134239)

  • 1. [Antithrombotic therapy in atrial arrhythmia].
    Cohen A
    Rev Prat; 2004 Feb; 54(3):298-307. PubMed ID: 15134239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter.
    Cairns JA; Connolly S; McMurtry S; Stephenson M; Talajic M;
    Can J Cardiol; 2011; 27(1):74-90. PubMed ID: 21329865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Antithrombotic treatment in atrial fibrillation. Background to new recommendations and therapeutic alternative].
    Själander A; Wallentin L; Rosenqvist M; Svensson P
    Lakartidningen; 2008 Sep 10-16; 105(37):2478-80. PubMed ID: 19006862
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of atrial fibrillation and atrial flutter: Part II.
    Aronow WS
    Cardiol Rev; 2008; 16(5):230-9. PubMed ID: 18708824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?].
    Selçuk H; Selçuk MT; Maden O
    Anadolu Kardiyol Derg; 2007 Mar; 7(1):54-8. PubMed ID: 17347079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of oral anticoagulants in complex clinical situations with atrial fibrillation.
    Gullón A; Sánchez Fuentes D; López-de-Sá E; Martí-Almor J; Barón-Esquivias G; Jiménez López J; Del Mar Contreras Muruaga M; Suárez Fernández C
    Med Clin (Barc); 2018 Jun; 150 Suppl 1():8-24. PubMed ID: 30502871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study.
    DiMarco JP; Flaker G; Waldo AL; Corley SD; Greene HL; Safford RE; Rosenfeld LE; Mitrani G; Nemeth M;
    Am Heart J; 2005 Apr; 149(4):650-6. PubMed ID: 15990748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ximelagatran: oral direct thrombin inhibition as anticoagulant therapy in atrial fibrillation.
    Halperin JL
    J Am Coll Cardiol; 2005 Jan; 45(1):1-9. PubMed ID: 15629364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cardiac arrhythmias in the elderly].
    Guize L; Piot O; Lavergne T; Le Heuzey JY
    Bull Acad Natl Med; 2006; 190(4-5):827-41; discussion 873-6. PubMed ID: 17195610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atrial fibrillation: rate control often better than rhythm control.
    Prescrire Int; 2004 Apr; 13(70):64-9. PubMed ID: 15148984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atrial fibrillation and anticoagulation.
    Garnier LF; Rouesnel P; Espitalier F
    Arch Mal Coeur Vaiss; 2004 Oct; 97(10):1001-5. PubMed ID: 16008178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials.
    Flaker GC; Gruber M; Connolly SJ; Goldman S; Chaparro S; Vahanian A; Halinen MO; Horrow J; Halperin JL;
    Am Heart J; 2006 Nov; 152(5):967-73. PubMed ID: 17070169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The clinical challenge of the atrial fibrillation].
    de Berrazueta Fernández JR
    An R Acad Nac Med (Madr); 2007; 124(2):361-78. PubMed ID: 18069601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Stroke with leg paralysis -- cardioversion in atrial fibrillation: prevention of thromboembolism in risk patients].
    MMW Fortschr Med; 2006 Jun; 148(23):58-9. PubMed ID: 16826742
    [No Abstract]   [Full Text] [Related]  

  • 15. [Anticoagulation in atrial fibrillation: not yet settled].
    Montagna R; Asenjo R; Madariaga R
    Rev Med Chil; 1998 Jun; 126(6):689-701. PubMed ID: 9778878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antithrombotic strategies for the management of non-valvular atrial fibrillation.
    Nixdorff U
    Int J Cardiol; 2005 Apr; 100(2):191-8. PubMed ID: 15823624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding.
    Douketis JD; Arneklev K; Goldhaber SZ; Spandorfer J; Halperin F; Horrow J
    Arch Intern Med; 2006 Apr; 166(8):853-9. PubMed ID: 16636210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contra: 'Warfarin should be the drug of choice for thromboprophylaxis in elderly patients with atrial fibrillation'. Caveats regarding use of oral anticoagulant therapy among elderly patients with atrial fibrillation.
    Hylek EM
    Thromb Haemost; 2008 Jul; 100(1):16-7. PubMed ID: 18612532
    [No Abstract]   [Full Text] [Related]  

  • 19. Antithrombotic therapy in atrial fibrillation: ximelagatran, an oral direct thrombin inhibitor.
    Halperin JL
    Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):163-74. PubMed ID: 15151465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antithrombotic therapies for stroke prevention in atrial fibrillation.
    Economides Muñoz C; Singh BN
    Minerva Cardioangiol; 2004 Apr; 52(2):125-39. PubMed ID: 15194994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.